Bacillus anthracis is the etiological agent of anthrax, a disease which affects domestic livestock and is frequently fatal. Humans can also become infected through contact with infected animals or animal products (4, 31) . Two virulence factors have been described for B. anthracis, a tripartite exotoxin (1, 34, 37) and a poly-D-glutamic acid capsule (26, 40, 41, 49) . The toxin and capsule have been shown to be encoded by separate plasmids contained in B. anthracis, pXO1 and pXO2, respectively (8, 27, 44) . Anthrax toxin is composed of protective antigen (PA), lethal factor (LF), and edema factor (EF). PA combines with EF or LF to form edema toxin or lethal toxin, respectively; however, individually, each of these three components is not toxic. Lethal toxin may cause death in rats, guinea pigs, and mice (1, 5, 6) . Intradermal injection of edema toxin causes edematous lesions in the skin (6, 36, 42) . Although the biological role of PA as a component of the anthrax toxin is not completely understood, evidence has been obtained suggesting that PA (83.5 kilodaltons [kDa]) initially binds to a specific cell surface receptor and is subsequently proteolytically cleaved by a trypsin-like protease to produce a receptor-bound 63.5-kDa fragment and a 20-kDa fragment, which is released from the cell surface (16) . The 63.5-kDa PA fragment is then bound competitively by LF or EF (16) . The resulting toxin complex is thought to enter cells by receptormediated endocytosis (7) , but the mechanism of cell death has not been determined. The poly-D-glutamic acid capsule contributes to disease virulence by inhibiting phagocytosis (14, 49) .
Vaccines of variable efficacy and safety have been developed and used for many years. The current livestock vaccine contains the spores of an attenuated, toxigenic, noncapsulated strain of B. anthracis, originally developed by Sterne (38) . In the United States, the licensed human vaccine consists of aluminum hydroxide-adsorbed supernatant material from fermentor cultures of V770-NP1-R, a toxigenic but noncapsulated strain of B. anthracis (32) . Effective immunization requires an initial course of three doses followed by three additional doses given at 6, 12, and 18 months * Corresponding author. (2) . Subsequent annual boosters are necessary to maintain immunization. The immunization schedule is effective but inefficient, since multiple doses over long periods of time are required. More recently, the efficacy of the human vaccine against certain strains of B. anthracis has been questioned (17) . PA appears to be the only essential component in an effective anthrax vaccine (6, 9, 10, 13) . The protective epitopes on PA appear to be those also involved in recognition of cell surface receptors, as the only two anti-PA monoclonal antibodies that neutralize anthrax toxin (lethal toxin and edema toxin) also prevent PA from binding to cell surface receptors (18) .
The primary objective of the studies described here was the development of vaccine candidates against B. anthracis which may be more efficacious and less reactogenic. Our approach has been to insert the PA gene into foreign vectors capable of expressing PA directly in animals or vectors capable of high expression rates in cell culture. The PA gene has been cloned, sequenced, and subsequently expressed in several procaryotic systems (12, 45) . Certain eucaryotic viruses are currently being explored as foreign gene expression systems and expression vectors for potential vaccine use. Autographa californica nuclear polyhedrosis virus is an insect virus (baculovirus) which can express foreign genes to unusually high levels when the gene is inserted into the polyhedrin gene of the virus (19, 23, 25, 28, 33, 35) . Vaccinia virus has been developed as a live, infectious expression vector for foreign genes inserted into the virus thymidine kinase gene (21, 22, 29, 30) . Insertion of the PA gene into vaccinia virus provided a eucaryotic recombinant vector capable of PA expression in vivo, whereas a baculovirus-PA gene recombinant produced PA efficiently in cell culture. Demonstrated here are the expression of PA in both virus systems, the antigenicity of these products, and the immunogenicity of expressed PA in mice.
MATERIALS AND METHODS
Viruses and cells. Vaccinia virus, strains Connaught (Con) and WR, and recombinants (Con-PA and WR-PA) were prepared, propagated, and assayed in Vero cells as described previously (3, 22) . All viral infections were initiated 
RESULTS
Construction of baculovirus-and vaccinia virus-PA recombinants. Insertion of the PA gene into baculovirus and vaccinia virus required subcloning into the appropriate virus transfer vectors (pAcYM1 and pSC-11, respectively). Figure  1 describes schematically the general procedures for gene insertion and recombinant virus selection. To excise the PA gene from pBLSCRPPA, two restriction endonuclease sites, a BglII site (nucleotide 3352) and a BamHI site (nucleotide 3335), were introduced by site-directed mutagenesis into two different pBLSCRPPA templates, pBLSCRPPA-1 and pBLSCRPPA-2, respectively. The PA gene was excised from pBLSCRPPA-1 with BglII and BamHI or from pBLSCRPPA-2 with BamHI and subcloned into the baculovirus transfer vector pAcYM1 (25) to produce plasmids pAcYM1-PA-1 and pAcYM1-PA-2. The PA gene was excised from pBLSCRPPA-1 with BglII and BamHI, and blunt ends were generated with the large fragment of DNA polymerase I and subcloned into the SmaI site of the vaccinia virus transfer vector pSC-11 (3) to produce pSC-11-PA.
Baculovirus recombinants were prepared by cotransfection of pAcYM1-PA-1 or pAcYM1-PA-2 and the baculovirus genome DNA into SF-9 cells followed by homologous recombination between polyhedrin sequences contained in both the baculovirus genome and pAcYM1. The PA gene was inserted into the baculovirus polyhedrin gene under control of the polyhedrin gene promoter. Baculovirus recombinants (lBac-PA and 2Bac-PA) were selected by terminal dilution of the initial recombinant virus mixture and hybridization to PA-specific nucleic acid probes. Vaccinia virus recombinants were generated by infection of Vero cells with vaccinia virus (strains WR or Connaught) followed by transfection of pSC-11-PA. The PA gene was inserted into the vaccinia virus thymidine kinase gene, under control of the vaccinia virus 7.5-kDa promoter, by homologous recombination between the thymidine kinase sequences in pSC-11 and vaccinia virus. Vaccinia virus recombinants (WR-PA and Con-PA) were selected from plaques that were positive for ,3-galactosidase expression. The lacZ gene is unique to the transfer vector pSC-11 (3).
Characterization and antigenicity of recombinant-expressed PA. Expression of the PA gene was detected by immunofluorescent antibody staining in both baculovirus recombinant-infected SF-9 cells harvested 72 h postinfection and vaccinia virus recombinant-infected Vero cells harvested 24 h postinfection. PA appeared to accumulate in the cytoplasm in both SF-9 and Vero cells, but the precise subcellular localization was not determined. Baculovirus recombinantinfected SF-9 cells were also examined by using 36 monoclonal antibodies against B. anthracis PA (18 (Fig. 2B, lanes 1 and 5) and continued to be produced through 24 h (lanes 2 through 4 and 6 through 8).
As seen with the baculovirus recombinant-expressed PA, the apparent molecular mass of the PA produced by the vaccinia virus recombinants was slightly larger (approximately 86 kDa) than that of B. anthracis-produced PA (lane 9). A number of PA-specific fragments were also observed (lanes 1 through 8) ; however, these fragments were different in size and quantity from those of baculovirus origin. Non The size difference observed between the recombinantexpressed PA and the B. anthracis-produced PA (Fig. 2) could be the result of a number of different co-or posttranslational processing events. Trypsin cleaves native PA of B. anthracis preferentially at one location to yield 63.5-(carboxy-terminal) and 20-(amino-terminal) kDa fragments (16 trypsin in an attempt to associate the PA size difl one or both primary fragments. Baculovirus rt expressed PA was concentrated by immunosorb tography (data not shown) with a PA-specific antibody (18, 20) . B. anthracis-produced PA X efficiently from 83.5 (Fig. 3, lane 1) to 63.5-fragments (lanes 2 through 4). Baculovirus rt expressed PA (lane 5) was also sensitive to dij trypsin and produced predominantly a 63.5-ki and a second fragment which was approximat (lanes 6 through 8). Therefore, the size differen bacterial and baculovirus recombinant-expressei appear to be associated with the amino-term] protein fragment.
Immunogenicity of recombinant-expressed P High anti-PA titers are found in animals immuni2 Sterne vaccine and several PA-producing bacte (10) (11) (12) 46 Therefore, we suggest a difference in the PA concentration per cell. PA expressed by these recombinants was immunogenic for mice. Serum titers were determined by antibody capture ELISA with bacterial PA. Therefore, the titers in animals reflected antibody that recognized authentic, toxin component PA. Anti-PA antibody titers were comparable to anti-PA antibody titers reported in other animals immunized with PA or PA-producing bacteria (10-13, 17, 43) . PA produced by 2Bac-PA appeared to immunize the animals better than did lBac-PA; however, an antigen capture ELISA demonstrated that 2Bac-PA-infected cells used to immunize animals contained six to eight times more PA per cell than the lBac-PA-infected cells (data not shown). Thus, the lower antibody titers presumably reflect a lower immunizing dose rather than a qualitative difference in the expressed immunogens. These results suggest that the anti-PA antibody titers are directly related to the amount of PA used to immunize the animals and demonstrate that baculovirus recombinant-expressed PA and vaccinia virus recombinants are capable of inducing high anti-PA titers in mice. The ability of these anti-PA antibodies to neutralize toxin and protect animals from a B. anthracis spore challenge is being explored currently.
